Introduction of EGFR
Epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase, expressed in 50% of non-small cell lung cancer (NSCLC) , which is closely related to the occurrence and development of tumors. The carcinogenic mutations of EGFR mostly occur in exons 18-21, of which 19 del and L858R account for 85% to 90% of all EGFR mutations , which are also the most common EGFR-TKI sensitive mutations. The T790M mutation suggests resistance to the first and second generation of EGFR-TKIs while sensitive to the third generation of EGFR-TKI. Both the National Comprehensive Cancer Network (NCCN) and the Chinese Society of Clinical Oncology (CSCO) guidelines have included EGFR mutation detection as a category 1 recommendation  . The guidelines also clearly stated that "When tumor tissue cannot be obtained or can be obtained for small amounts ,EGFR mutation detection can be performed through peripheral blood /tumor DNA (cf/ctDNA) ".
 Nat Rev Cancer. 2007 Mar;7(3):169-81.
 NCCN Clinical Diagnosis and Treatment Guidelines NSCLC 2021 V76
 CSCO NSCLC Diagnosis and Treatment Guidelines 2021
Introduction of ctDNA
ctDNA is released into blood vessels by tumor cells or circulating tumor cells through apoptosis, necrosis, phagocytosis, or active secretion. It can reflect the real-time tumor load in the body, dynamically monitor the efficacy of drugs, and predict disease changes early. ctDNA has become a dynamic biomarker based on plasma, which plays an important role in the fields of early tumor diagnosis, molecular typing, targeted drug selection, and monitoring of minimal residual disease. Since the content of ctDNA is usually less than 1% of the total cfDNA of an individual , screening ctDNA from a large amount of cfDNA requires high detection sensitivity. Liquid biopsy technology based on digital PCR makes its possible to detect low concentrations of ctDNA.ctDNA is released into the blood
Gefitinib, Erlotinib, Icotinib, Afatinib, Osimitinib,
|T790M||Osimitinib, Almonertinib, Furmonertinib|
|Sample Type||Matched Instrument|
|Human EGFR Gene |
|EGFR-T790M||Digital PCR||10 tests/kit|
Human EGFR Gene
Human EGFR Gene
19 del Mutation
1.The detection of EGFR mutation for stage II/III non-squamous cell carcinoma after operation can help guide adjuvating targeted therapies.
2. It is recommended to detect EGFR gene status before first line treatment for patients with inoperable stage III and IV NSCLC to guide the treatments according to molecular classification. If tissue samples are not available, circulating tumor DNA can be considered for testing.
3.For patients with EGFR-TKI resistance, EGFR T790M gene mutation detection is recommended. If tissue samples are not available, circulating tumor DNA can be considered for testing.
4. Regularly monitor T790M resistance mutations after using EGFR-TKI drugs.
High Sensitivity: This kit can detect as low as 0.1% mutation in DNA sample.
Precise Quantification：Quantitative detection of gene mutation abundance, timely detection of disease progression, and adjustment of treatment plans.
No internal reference needed: Avoid fake negative.
Easy operation: Only 1 day for the detection process.3 working days from sample to report.